Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alopecia Areata | Treatment Algorithms: Claims Data Analysis | US | 2024

Login to access report north_east
Contact sales account_box

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids and topical or contact immunotherapy are commonly prescribed. Two JAK inhibitors—Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Litfulo (ritlecitinib)—are approved for severe AA. As the treatment landscape continues to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices in AA and to define the market niche for emerging products.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
  • How has Olumiant been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key drugs: Contact allergens, corticosteroids, cyclosporine A, finasteride, Litfulo, Jakafi, methotrexate, Olumiant, pimecrolimus, retinoids, tacrolimus (topical), Xeljanz

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east